Ferroportin disease is caused by mutation of one allele of the iron exporter 
Introduction
Hereditary hemochromatosis is a common disorder in humans characterized by iron overload resulting in tissue injury and ultimately organ failure. Typically hemochromatosis exhibits an autosomal recessive pattern of inheritance and is associated with mutations in HFE, hemojuvelin, hepcidin or transferrin receptor-2 1, 2 . Targeted deletion of these genes in the mouse results in hemochromatosis providing mouse models for most forms of the disease.
Hemochromatosis type IV, also referred to as Ferroportin (Fpn) disease results from mutations in the iron transporter ferroportin. Fpn is the only known iron exporter in mammalian cells and is present on the surface of macrophages, intestinal enterocytes, hepatocytes and placental cells [16] [17] [18] . The level of cell surface Fpn is regulated by its interaction with hepcidin, a peptide secreted by the liver in response to iron stores and inflammation. Hepcidin binds to Fpn For personal use only. on October 28, 2017. by guest www.bloodjournal.org From inducing its internalization and degradation, thus regulating the export of iron from cells to plasma 3 .
Mutations in Fpn lead to iron-overload disease but, in contrast to other forms of hemochromatasis, Ferroportin disease exhibits an autosomal dominant pattern of inheritance 4 . The disorder has different presentations depending upon the Fpn mutation. Mutations that lead to Fpn that is not internalized by hepcidin result in iron accumulation in hepatocytes and high transferrin saturation 5, 6 . Mutations that lead to Fpn that is not appropriately targeted to the cell surface result in iron accumulation in Kupffer cells and low transferrin saturation [6] [7] [8] . The mechanism by which the disease mutations exert a dominant effect is unclear. Some groups who study the disease suggest that it results from haploinsufficiency 7, 9 while others suggest that the disorder results from a dominant negative effect of the mutant allele 6, 10 . Importantly, all human mutations are missense mutations and mice that are heterozygous for a targeted deletion of Fpn do not show the disease 11 . Treatment for hemochromatosis aims to decrease iron load by repeated phlebotomy and this treatment works well for most patients. Many patients with Ferroportin disease, however, become anemic with phlebotomy, highlighting the need for a mouse model to develop better treatments.
We report here on a missense mutation in mouse Fpn that results in a disorder that is identical to classic human ferroportin disease. We show that macrophages isolated from mutant mice have no Fpn on their cell surface and that expression of Fpn constructs containing the missense mutation (H32R) affects the behavior of wild type Fpn. These results show that Fpn disease is due to a dominant negative effect of the mutant allele and provide the first mouse model for this disorder.
Methods
Generation of mutant mice and identification of Fpn mutation. The ffe mouse line was identified in a screen for recessive ENU-induced mutations that cause morphological abnormalities at E12.5 [12] [13] [14] . The ffe mutation was Step RT-PCR, Invitrogen) using RNA isolated from E10.5 ffe/ffe and C57BL/6 control embryos. Sequencing was confirmed using DNA isolated from ten additional ffe/ffe mutant embryos.
Prussian Blue staining. Livers were fixed overnight in 4% paraformaldehyde, cryopreserved in 30% sucrose, embedded in OCT compound (Tissue-Tek) and sectioned at 10 mM. Fixed frozen sections were incubated in hydrochloric acid (10%) and potassium ferrocyanide (5%) as described (http://www.ihcworld.com) and counterstained with eosin.
Constructs and cells. The cloning and expression of mouse Fpn in a CMV-
containing vector (pEGFP-N1, Clontech or pCMV-Tag4 (FLAG), Stratagene) was described previously 6 . pEGFP-FpnH32R was generated in pFpn-EGFP-N1 by using the QuikChange Site-Directed Mutagenesis Kit (Stratagene), amplified in Escherichia coli and sequence-verified. HEK293T cells were maintained in Dulbecco's minimal essential media (DMEM) with 10% fetal bovine serum and were transfected with pFpn-GFP and pFpn(H32R)-GFP or pFpn-FLAG using Nucleofector technology (Amaxa, Gaithersburg, MD) according to the manufacturer's directions. Mouse bone marrow macrophages were harvested from femurs and maintained as described previously 15 .
Erythrophagocytosis. Erythrophagocytosis was performed as described Western analysis was performed as described previously 6 using rabbit anti-Fpn
(1:500) and mouse anti-human a-tubulin (1:5,000) followed by either peroxidase conjugated goat anti-rabbit IgG (1:12,500, Jackson ImmunoResearch Labs) or peroxidase conjugated goat anti-mouse IgG (1:12,500, Jackson
ImmunoResearch Labs). Mice were bled retro-orbitally and peripheral blood smears were stained with Wright-Giemsa. Ferritin analysis was performed as described 3 . Transferrin saturation was determined by means of a ferrozinebased iron and total iron-binding capacity assay (Teco Diagnostic). Protein concentration was measured using the BCA assay (Pierce). All experiments were repeated a minimum of three times.
Results
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The flatiron (ffe) mutation is in the Fpn gene In a screen for recessive mutations induced by ethylnitrosurea that affect development of the mouse embryo, we identified ffe as a recessive mutation that causes developmental defects on a mixed C3H/HeJ X C57BL/6 background including neural tube closure defects, microphthalmia, forebrain truncations, generalized edema, severe anemia and mid-gestation lethality (data not shown).
When the ffe mutation was crossed onto the 129/SvJ inbred strain, homozygous mutant embryos showed only severe anemia and mid-gestation lethality ( Figure   1a ,b). Using a positional cloning strategy, the ffe mutation was mapped to a 2. Most Fpn null/null embryos die by E7.5 11 due to defects in iron transfer across the visceral endoderm, indicating that Fpn ffe is a hypomorphic allele of Fpn. It is likely that the more complex phenotype seen in the original mutant was due to the background strain as the complex phenotype was lost when the mice were bred onto different backgrounds.
The ffe mutation results in mislocalization of Fpn
The cell surface localization of Fpn is essential for its function (Figure 3a,b) It has been suggested that mutations in Fpn might result in cellular iron overload due to haploinsufficiency 7, 9 , however, mice that are heterozygous for a targeted gene deletion of Fpn do not show evidence of iron-overload disease 11 .
To further explore the possibility that haploinsufficiency could explain decreased iron export, we used RNAi to silence mouse Fpn in macrophages. Cells were transfected with non-specific oligonucleotides or different concentrations of oligonucleotides specific to mouse Fpn. After 24 hours, cells were loaded with iron and levels of Fpn and cellular ferritin were determined 48 hours post transfection. Macrophages showed almost normal levels of iron export even when Fpn protein levels were decreased by 50% (Figure 3d ). Reduction in iron export activity (higher levels of ferritin) did not occur until Fpn levels decreased to below 30% of wild type levels. These results indicate that half normal levels of 5, 6 . Other patients present with an early rise in ferritin levels, low to normal transferrin saturation and iron accumulation primarily in Kupffer cells.
This presentation is associated with Fpn mutations that affect its plasma membrane localization or iron export activity 5, 6 . Serum ferritin levels in Fpn ffe/+ heterozygous animals were 10-fold increased over 6-month old control animals and increased with age ( Figure 4a ). In addition, transferrin saturation in serum 5, 8, 22 . 
